Cytos Biotechnology AG

EQS-Adhoc: Cytos Biotechnology Ltd exclusively licenses its VLP platform for the treatment of Cancer to Checkmate Pharmaceuticals LLC

EQS Group-Ad-hoc: Cytos Biotechnology AG / Key word(s): Agreement
Cytos Biotechnology Ltd exclusively licenses its VLP platform for the
treatment of Cancer to Checkmate Pharmaceuticals LLC

12.08.2015 / 07:00
Release of an ad hoc announcement pursuant to Art. 53 KR.
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------

Cytos exclusively licenses its VLP platform for the treatment of Cancer to
Checkmate Pharmaceuticals LLC

Schlieren (Zurich), Switzerland, August 12, 2015 - Cytos Biotechnology Ltd.
(SIX:CYTN) ("Cytos") announced today that it executed an exclusive license
agreement in the field of oncology granting Checkmate Pharmaceuticals LLC,
Cambridge, MA, USA ("Checkmate") exclusive access to Cytos' clinically
validated product candidate CYT003 as well as its VLP platform and to
technology related to oligonucleotide synthesis.

Cytos may receive up to USD 90 million in development milestones and may
receive up to double-digit royalties on net sales from successfully
developed products.

"We are excited about the potential of our immunologically active VLP
platform in the field of immune-oncology and believe that Checkmate is well
positioned to advance treatment options for patients with cancer",
commented Christian Itin, Chairman and CEO of Cytos.

For further information, please contact:

Cytos Biotechnology Ltd
Harry Welten, MBA
Chief Financial Officer
Tel: +41 44 733 46 46
harry.welten@cytos.com

About Cytos Biotechnology Ltd

Cytos is a public biopharmaceutical company located in Schlieren (Zurich),
Switzerland. The Company is listed according to the Main Standard on the
SIX Swiss Exchange Ltd under the symbol CYTN. Website: www.cytos.com

About Checkmate

Checkmate Pharmaceuticals is a research and development company pursuing a
novel approach to specifically activating the innate arm of the immune
system to recognize and ultimately destroy tumor cells. The company is
leveraging their expertise and the vast body of knowledge in the field of
CpG oligonucleotides and is validating an approach that will combine the
ability of CpG DNA to activate an anti-tumor T cell response with
checkpoint inhibition to overcome a tumor's ability to mute the immune
response. Checkmate's founder and CEO, Dr. Art Krieg, discovered CpG DNA in
1994 and since then CpG DNAs have been administered to thousands of humans
showing potent immune activation and an excellent safety profile. Checkmate
is a privately held company headquartered in Cambridge, Mass. Information
regarding Checkmate is available on the company's web site at
www.checkmatepharma.com.

Forward Looking Statements
This media release contains certain forward-looking statements that involve
risks and uncertainties that could cause actual results to be materially
different from historical results or from any future results expressed or
implied by such forward-looking statements. You are urged to consider
statements that include the words "will" or "expect" or the negative of
those words or other similar words to be uncertain and forward-looking.
Factors that may cause actual results to differ materially from any future
results expressed or implied by any forward-looking statements include
scientific, business, economic and financial factors, Against the
background of these uncertainties, readers should not rely on
forward-looking statements. The Company assumes no responsibility for
updating forward-looking statements or adapting them to future events or
developments.

End of ad hoc announcement

+++++
Additional features:

Document: http://n.equitystory.com/c/fncls.ssp?u=TAFVQMBTJS
Document title: Cytos Checkmate agreement 150812

---------------------------------------------------------------------

12.08.2015 News transmitted by EQS Schweiz AG. www.eqs.com - news
archive: http://switzerland.eqs.com/de/News

The issuer is responsible for the contents of the release.

---------------------------------------------------------------------


Language:    English
Company:     Cytos Biotechnology AG
             Wagistr. 25
             8952 Schlieren
             Switzerland
Phone:       +41 44 733 4747
Fax:         +41 44 733 4740
E-mail:   info@cytos.com
Internet: www.cytos.com
ISIN:        CH0011025217, CH0029060735
Valor:       -
Listed:      Regulated Unofficial Market in Berlin, Munich, Stuttgart;
             Open Market in Frankfurt ; SIX


End of News    EQS Group News-Service
---------------------------------------------------------------------
385741 12.08.2015
 



Weitere Meldungen: Cytos Biotechnology AG

Das könnte Sie auch interessieren: